Jun 2026 (Q2 FY26) — Aug 4, 2026
TransMedics Q2 FY26 — Record Revenue and Strategic Growth Investments
Read the full callTransMedics (TMDX) earnings
- Jun 2026
- Jun 2026 (Q2 FY26)
- Dec 2025
TransMedics earnings: last reported Tue, 4 Aug 2026, for the quarter ended Jun 2026.
Reported
The figures, each with its period
Each figure keeps its basis and period; nothing is filled in.
| Metric | Value | Change | Basis | Period | Note |
|---|---|---|---|---|---|
| Revenue | 190 | +20.7% YoY | Quarterly, as filed | Quarter to Jun 2026 | Revenue from operations as filed. |
| Operating margin | 12.5 | −10.7 pts YoY | Operating profit / revenue | Quarter to Jun 2026 | For the quarter; a change is in percentage points. |
| Net profit | 14.7 | −57.9% YoY | Quarterly, as filed | Quarter to Jun 2026 | Profit after tax as filed. |
Price
$71.6 +1.16% · +$0.82
Performance −39.1% 1Y
1Y: $117.63 on 17 Oct 2025 → $71.6. High $150.42 (1 Dec 2025), low $62.04 (14 May 2026).
- Previous close
- $70.78
- 52-week range
- $62.04 – $150.42
- One year
- −40.28%
Overview
- Symbol
- TMDX
- Sector
- Health Care
- Exchange
- US
- Currency
- USD
Call summaries
Every analysed call
TransMedics earnings calls (TMDX)
Financials
What the filings say
Net profit, year on year: −58% (quarter to jun 2026 against jun 2025).
| Line item | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Sales | 109 | 122 | 144 | 157 | 144 | 161 | 174 | 190 |
| Operating profit | 4 | 9 | 27 | 37 | 23 | 21 | 13 | 24 |
| Operating margin | 3.6% | 7.1% | 19.1% | 23.2% | 16.2% | 13.2% | 7.6% | 12.5% |
| Other income | 0 | -2 | -1 | -0 | -0 | 0 | -5 | -4 |
| Interest | 4 | 4 | 3 | 3 | 3 | 3 | 7 | 7 |
| Profit before tax | 4 | 7 | 27 | 36 | 23 | 22 | 8 | 19 |
| Tax rate | 0.7% | 1.9% | 3.7% | 3.5% | −5.6% | −387.1% | 13.8% | 24.3% |
| Net profit | 4 | 7 | 26 | 35 | 24 | 105 | 7 | 15 |
| EPS ($ per share) | 0.13 | — | 0.76 | 1.03 | 0.71 | — | 0.21 | 0.42 |
| Line item | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|
| Equity capital | 0 | 424 | 502 | 510 | 666 | 641 | 697 | 751 |
| Reserves | -336 | -369 | -398 | -442 | -479 | -504 | -468 | -278 |
| Total liabilities | 48 | 51 | 48 | 67 | 90 | 569 | 575 | 595 |
| Fixed assets | 3 | 5 | 5 | 10 | 19 | 174 | 286 | 328 |
| Investments | — | 61 | 101 | 67 | — | — | — | — |
| Total assets | 42 | 105 | 152 | 135 | 277 | 706 | 804 | 1,068 |
| Line item | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|
| Cash from operations | -26 | -32 | -30 | -29 | -46 | -13 | 49 | 193 |
| Cash from investing | 12 | -61 | -42 | 29 | 55 | -194 | -129 | -59 |
| Cash from financing | 22 | 93 | 76 | 1 | 168 | 400 | 23 | 17 |
| Net cash flow | 8 | -0 | 4 | 1 | 176 | 194 | -58 | 152 |
| Capital expenditure | -0 | -0 | -0 | -4 | -12 | -152 | -130 | -59 |
| Free cash flow | -26 | -32 | -31 | -32 | -58 | -165 | -81 | 134 |
Insider filings
35 filings between Oct 29, 2025 and Sep 11, 2026.
Open market
decisions to buy or sellPurchases
$1.11M
2 purchases by 2 insiders
Sales
$4.87M
12 sales by 7 insiders
8% filed under a 10b5-1 plan — scheduled in advance, not decided on the day
Compensation
not trading decisions- 12
- Award — granted as compensation
- 7
- Option exercise — converted options into shares
- 1
- Tax withheld — shares kept back by the company to cover tax
Also filed: 1 gift.
Who traded
open market only| Insider | Bought | Sold | Last filing |
|---|---|---|---|
| Weill David | $109.1K | $1.22M | Sep 11, 2026 |
| Hernandez Gerardo | — | $1.25M | Mar 4, 2026 |
| Hassanein Waleed H | $1.00M | — | Nov 17, 2025 |
| Gunderson Thomas James | — | $722.4K | Jun 15, 2026 |
| Ranganath Anil P. | — | $555.9K | Mar 2, 2026 |
| Basile Edward M | — | $540.3K | Oct 29, 2025 |
| Corcoran Nicholas | — | $412.6K | Mar 2, 2026 |
| Lovell Stephanie | — | $178.5K | Mar 4, 2026 |
Latest filings (50)
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| Sep 11, 2026 | Weill David Director | Purchase | 1,336 | $109.1K |
| Aug 17, 2026 | TOBIN JAMES R Director | Gift | 18,000 | $0 |
| Jul 10, 2026 | Corcoran Nicholas See remarks | Award | 11,727 | $0 |
| Jul 10, 2026 | Hernandez Gerardo Chief Financial Officer | Award | 17,246 | $0 |
| Jul 10, 2026 | Hassanein Waleed H President & CEO | Award | 49,669 | $0 |
| Jun 15, 2026 | Gunderson Thomas James Director | Option exercise | 19,285 | $42.6K |
| Jun 15, 2026 | Gunderson Thomas James Director | Sale | 9,624 | $722.4K |
| May 20, 2026 | Weill David Director | Award | 2,922 | $0 |
| May 20, 2026 | KANIA EDWIN M JR Director | Award | 2,922 | $0 |
| May 20, 2026 | Lovell Stephanie Director | Award | 2,922 | $0 |
| May 20, 2026 | RAINES MERILEE Director | Award | 2,922 | $0 |
| May 20, 2026 | Gunderson Thomas James Director | Award | 2,922 | $0 |
| May 20, 2026 | Basile Edward M Director | Award 10b5-1 plan | 2,922 | $0 |
| May 20, 2026 | TOBIN JAMES R Director | Award | 2,922 | $0 |
| May 19, 2026 | Forsyth Matthew S. See Remarks | Award | 15,409 | $0 |
| Mar 4, 2026 | Lovell Stephanie Director | Sale | 1,193 | $178.5K |
| Mar 4, 2026 | Weill David Director | Sale | 3,571 | $524.3K |
| Mar 4, 2026 | Weill David Director | Option exercise | 3,571 | $50.7K |
| Mar 4, 2026 | Hernandez Gerardo Chief Financial Officer | Sale | 5,912 | $870.3K |
| Mar 4, 2026 | Hernandez Gerardo Chief Financial Officer | Option exercise | 5,912 | $412.9K |
| Mar 4, 2026 | Hernandez Gerardo Chief Financial Officer | Sale | 1,324 | $194.9K |
| Mar 4, 2026 | Hernandez Gerardo Chief Financial Officer | Option exercise | 1,324 | $102.1K |
| Mar 2, 2026 | Hernandez Gerardo Chief Financial Officer | Sale | 375 | $52.2K |
| Mar 2, 2026 | Ranganath Anil P. See remarks | Sale | 864 | $120.2K |
| Mar 2, 2026 | Corcoran Nicholas See remarks | Sale | 2,966 | $412.6K |
| Feb 18, 2026 | Cecere Giovanni Chief Commercial Officer | Award | 11,082 | $0 |
| Jan 23, 2026 | Corcoran Nicholas See remarks | Tax withheld | 984 | $133.1K |
| Dec 4, 2025 | Hernandez Gerardo Chief Financial Officer | Sale | 920 | $128.5K |
| Dec 3, 2025 | Weill David Director | Sale | 5,000 | $693.2K |
| Dec 3, 2025 | Weill David Director | Option exercise | 5,000 | $71.0K |
| Nov 25, 2025 | Ranganath Anil P. See remarks | Sale | 3,000 | $435.7K |
| Nov 25, 2025 | Ranganath Anil P. See remarks | Option exercise | 3,000 | $281.6K |
| Nov 17, 2025 | Hassanein Waleed H President & CEO | Purchase | 8,775 | $1.00M |
| Oct 29, 2025 | Basile Edward M Director | Option exercise 10b5-1 plan | 4,142 | $2.9K |
| Oct 29, 2025 | Basile Edward M Director | Sale 10b5-1 plan | 4,142 | $540.3K |
| Aug 7, 2025 | Hassanein Waleed H President & CEO | Purchase | 1,858 | $217.1K |
| Aug 7, 2025 | Hassanein Waleed H President & CEO | Purchase | 6,617 | $768.1K |
| Aug 6, 2025 | Hassanein Waleed H President & CEO | Purchase | 8,400 | $996.9K |
| Aug 4, 2025 | Basile Edward M Director | Sale 10b5-1 plan | 4,143 | $520.0K |
| Aug 4, 2025 | Basile Edward M Director | Option exercise 10b5-1 plan | 4,143 | $2.9K |
| Jun 9, 2025 | Ranganath Anil P. See remarks | Sale | 686 | $95.9K |
| May 27, 2025 | Basile Edward M Director | Option exercise 10b5-1 plan | 5,000 | $3.5K |
| May 27, 2025 | Basile Edward M Director | Sale 10b5-1 plan | 5,000 | $632.3K |
| May 23, 2025 | Weill David Director | Sale | 732 | $90.7K |
| May 22, 2025 | Basile Edward M Director | Award | 2,134 | $0 |
| May 22, 2025 | Lovell Stephanie Director | Award | 2,134 | $0 |
| May 22, 2025 | TOBIN JAMES R Director | Award | 2,134 | $0 |
| May 22, 2025 | RAINES MERILEE Director | Award | 2,134 | $0 |
| May 22, 2025 | Gunderson Thomas James Director | Award | 2,134 | $0 |
| May 22, 2025 | KANIA EDWIN M JR Director | Award | 2,134 | $0 |
Source: SEC Form 4 filings. Form 4 reports transactions, not the cap table — absence of filings says nothing about how much an insider owns, and a quiet window is not a signal.
Your own record
Start an Inve Case for TransMedics Group, Inc.
Free account. Everything above stays public.
Write why you follow TransMedics Group, Inc. and the condition you want checked. Inve compares your numeric conditions with available results and management guidance; your own conditions remain yours to review.
Keep reading